Based on the Pharming Group N.V stock forecast from 0 analysts, the average analyst target price for Pharming Group N.V is not available over the next 12 months. Pharming Group N.V’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Pharming Group N.V is Slightly Bearish, which is based on 6 positive signals and 8 negative signals. At the last closing, Pharming Group N.V’s stock price was USD 0.79. Pharming Group N.V’s stock price has changed by -12.61% over the past week, -9.09% over the past month and -34.17% over the last year.
No recent analyst target price found for Pharming Group N.V
No recent average analyst rating found for Pharming Group N.V
Company Overview Pharming Group N.V
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. Read Less
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibit...Read More
Frequently Asked Questions About Pharming Group N.V (PHGUF) Stock
Stock Target Advisor's fundamental analysis for Pharming Group N.V's stock is Slightly Bearish.
Unfortunately we do not have enough data on PHGUF's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PHGUF's stock to indicate what its average analyst target is.
PHGUF stock's Price/Earning ratio is 58.50.
Our analysis grades PHGUF stock's Price / Earning ratio at F. This means that PHGUF stock's Price/Earning ratio is above 86% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this PHGUF may be a overvalued for its sector.
The last closing price of PHGUF's stock was USD 0.79.
The most recent market capitalization for PHGUF is USD 0.63B.
Unfortunately we do not have enough analyst data on PHGUF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Pharming Group N.V's stock.
As per our most recent records Pharming Group N.V has 382 Employees.
Pharming Group N.V's registered address is Darwinweg 24, Leiden, Netherlands, 2333 CR.
You can get more information about it from Pharming Group N.V's website at https://www.pharming.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Pharming Group N.V (PHGUF) Stock
Stock Target Advisor's fundamental analysis for Pharming Group N.V's stock is Slightly Bearish.
Unfortunately we do not have enough data on PHGUF's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PHGUF's stock to indicate what its average analyst target is.
PHGUF stock's Price/Earning ratio is 58.50.
Our analysis grades PHGUF stock's Price / Earning ratio at F. This means that PHGUF stock's Price/Earning ratio is above 86% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this PHGUF may be a overvalued for its sector.
The last closing price of PHGUF's stock was USD 0.79.
The most recent market capitalization for PHGUF is USD 0.63B.
Unfortunately we do not have enough analyst data on PHGUF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Pharming Group N.V's stock.
As per our most recent records Pharming Group N.V has 382 Employees.
Pharming Group N.V's registered address is Darwinweg 24, Leiden, Netherlands, 2333 CR.
You can get more information about it from Pharming Group N.V's website at https://www.pharming.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PHGUF !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
